Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Zevra Therapeutics's Debt-to-EBITDA or its related term are showing as below:
ZVRA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.99 Med: -1.34 Max: 0.64
Current: 0.02
During the past 13 years, the highest Debt-to-EBITDA Ratio of Zevra Therapeutics was 0.64. The lowest was -12.99. And the median was -1.34.
ZVRA's Debt-to-EBITDA is ranked better than 97.11% of 311
companies
in the Biotechnology industry
Industry Median: 1.39
vs ZVRA: 0.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Zevra Therapeutics Debt-to-EBITDA Related Terms
Zevra Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Zevra Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZVRA vs TECX, RLMD, ALT: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Zevra Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Zevra Therapeutics (ZVRA) has a Debt-to-EBITDA of 0.03 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Zevra Therapeutics. According to the industry distribution chart, Zevra Therapeutics ranks #9 out of 311 companies in the Biotechnology industry, placing it in the top 2.9%.
Is Zevra Therapeutics' Debt-to-EBITDA too high?
Zevra Therapeutics' current Debt-to-EBITDA is 0.03. The Biotechnology industry median Debt-to-EBITDA is 1.39. Zevra Therapeutics' value of 0.03 is 97.8% below this industry median. Based on the distribution chart, Zevra Therapeutics ranks #9 out of 311 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zevra Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' Debt-to-EBITDA compare to TECX and RLMD?
According to the Biotechnology industry distribution chart, Zevra Therapeutics ranks #9 out of 311 companies for Debt-to-EBITDA. This places Zevra Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.39. Zevra Therapeutics' value of 0.03 is 97.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.39, based on 311 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zevra Therapeutics's current Debt-to-EBITDA of 0.03 is 97.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Zevra Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zevra Therapeutics's current Debt-to-EBITDA is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (ZVRA) is currently considered Possible Value Trap. The stock's GF Value™ is $21.07, compared to a current price of $11.87 — trading 43.7% below its estimated fair value. The current Debt-to-EBITDA is 0.03 and 97.8% below the Biotechnology industry median of 1.39. Zevra Therapeutics' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Zevra Therapeutics (ZVRA), the current Debt-to-EBITDA is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zevra Therapeutics (ZVRA) Overvalued in 2026?
Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued.
The current stock price of $11.87 is trading 43.7% below its estimated GF Value™ of $21.07.
GuruFocus considers Zevra Therapeutics to be Possible Value Trap.
Key valuation signals for ZVRA:
Debt-to-EBITDA: 0.03
GF Value™: $21.07 vs. price of $11.87 (43.7% below fair value)
Industry Position: 97.8% below the Biotechnology median (#9 of 311)
No single metric tells the full story. See the ZVRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
68GF Score
Get the complete analysis for ZVRA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZVRA has been successfully added to your 
